News & Updates

TC-325, a bentonite haemostatic powder with aluminium phyllosilicate clay as the main ingredient, is found to be comparable to standard treatment in controlling active upper gastrointestinal bleeding, according to results of a randomized clinical trial by the Chinese University of Hong Kong (CUHK), King Chulalongkorn Memorial University Hospital in Thailand, and Changi General Hospital in Singapore.

The addition of mogamulizumab to nivolumab falls short of improving efficacy of the latter in the treatment of patients with locally advanced or metastatic solid tumours, according to the results of a phase I/II trial.

In the management of virologically suppressed patients living with HIV, efavirenz 400 mg has noninferior efficacy and favourable safety as compared with the 600 mg-based regimen, according to a study from China.

Treatment with topical recombinant human nerve growth factor (rhNGF) is safe and well tolerated but falls short of providing neuroprotection in patients with glaucoma, according to the results of a phase Ib study.

Giving adjuvant S-1 to patients with curatively resected biliary tract cancer (BTC) significantly improves survival compared with observation following surgery, according to the ASCOT trial presented in the 2022 ASCO Gastrointestinal Cancers Symposium (GICS).